The movement toward personalized medicine has created an increased market demand for biomarkers which can detect early sign of disease, assess disease prognosis, predict treatment outcome, and manages disease activity. With a strong foothold in antibody manufacturing and antibody-based system integration in profiling and quantification, Abnova, a company for which Novus Biologicals distributes, has made a seamless transition and foray into the in vitro diagnostic (IVD) market.